Preferred Label : t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript/control transcript:NRto:Pt:Bld/Tiss:Qn:Molgen;
LOINC status : ACTIVE;
LOINC display name : t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript/control transcript Molgen (Bld/Tiss)
[# ratio];
LOINC long common name : t(1;19)(q23.3;p13.3)(PBX1,TCF3) fusion transcript/control transcript [# Ratio] in
Blood or Tissue by Molecular genetics method;
LOINC short name : t(1;19)(PBX1,TCF3)/control Bld/T;
LOINC description : A translocation involving chromosomes 1 and 19, t(1;19)(q23;p13), results in a fused
transcript between TCF3 (formerly E2A) and PBX1 (formerly prl) genes. The TCF3-PBX1
fusion gene is found in approximately 3% of childhood and adult precursor-B acute
lymphoblastic leukemia (ALL). This code is based on, but not limited to, Ispogen's
E2A-PBX1 FusionQuant kit, which uses real-time Quantitative RQ-PCR to quantify the
expression level of specific TCF3(E2A)-PBX1 fusion gene transcripts relative to a
control gene transcript (e.g. ABL1). From the manufacturer's website (2012), Quantification
of E2A-PBX1 fusion gene transcripts has been standardized in the EAC (Europe Against
Cancer) program [Gabert J et al. Leukemia. 2003, Beillard E et al. Leukemia. 2003],
and IPSOGEN FusionQuant kits use this validated technology to calibrate and normalize
RQ-PCR results.;
Origin ID : 72312-2;
UMLS CUI : C3533750;
Has component
- Has method
- Has property
- Has system
- Has time aspect
- Part of panel
- Semantic type(s)
